swissmedic

CERTIFICATE OF GMP COMPLIANCE

We certify herewith

that the company **Future Health Biobank SA, Route de Pra-de-Plan 3, 1618 Châtel-St-Denis, Switzerland**, has been duly authorized to manufacture and distribute transplant products, the manufacturing licence includes sterile products and includes the following product categories:

- not ready to use cell therapy products for autologous use or allogenic use
- not ready to use tissue products for autologous use or allogenic use

Restrictions:
Manufacturing is limited to storage of starting material for the manufacture of cell therapy products and tissue products

that the company is keeping the required level for good practices in the manufacture of transplant products according to the Swiss regulations in force. These regulations are in accordance with the requirements for good practices in the manufacture and quality control of the Pharmaceutical Inspection Convention /Co-operation Scheme (PIC/S) and the Directives of the European Commission;

that the manufacturing plant of the company is subject to official periodic inspections; the last regular inspection was conducted on **April 26 - 27, 2017**;

Berne, September 24, 2018
No. 18-2049

Swissmedic, Swiss Agency for Therapeutic Products

Dr. Federico Cimini

Swiss Agency for Therapeutic Products
swissmedic

Schweizerisches Heilmittelinstitut
Institut suisse des produits thérapeutiques
Istituto svizzero per gli agenti terapeutici
Swiss Agency for Therapeutic Products

Swissmedic | Hallerstrasse 7 | Postfach | CH-3000 Bern 9 | www.swissmedic.ch | Tel. +41 58 462 02 11 | Fax +41 58 462 02 12